rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INTS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Intensity Therapeutics Q3 2026 Earnings Call Transcript
      Nov 5BenzingaINTS
      Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 5MorningstarINTS
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Oct 30BenzingaINTSNRXP
      Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
      Oct 30MorningstarINTS
      Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO)
      Oct 23Yahoo FinanceINTS
      Intensity Therapeutics at H.C. Wainwright conference: data, cash and catalysts
      Sep 11Investing.comINTS
      Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
      Sep 8MorningstarINTS
      All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

      Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Sep 2Yahoo FinanceACTUINTS

      This is the newest page. Registered accounts read further back.